technische universitaet muenchen

New class of drugs for the reversible inhibition of proteasomes

EurekAlert! - Cancer  Mon, 11/21/2011 - 23:00

(Technische Universitaet Muenchen) Based on a high throughput screening of a substance library biochemists at the Technische Universitaet Muenchen have identified the lead structure of a new class of drugs that reversibly blocks the proteasome by a previously unknown binding mechanism.

New medication not only against cancer could be developed on the basis of this new mechanism. The "Early View" of the international edition of Angewandte Chemie reports on their results.


 

Radionuclide treatment against small tumors and metastases

EurekAlert! - Cancer  Wed, 06/15/2011 - 22:00

(Technische Universitaet Muenchen) Medicine could very soon have a new ally in the fight against cancer: Terbium-161.

Its most important weapon: Conversion and Auger electrons. Researchers at the Technische Universitaet Muenchen have developed a new treatment method based on terbium-161 to treat smaller tumors and metastases in a more targeted way.

The nuclide was produced at the TUM's research neutron source. In cooperation with the Paul Scherrer Institute it has been tested on cancer cells successfully.


 

Sport doctors say non-alcoholic wheat beer boosts athletes' heal...

EurekAlert! - Infectious and Emerging Diseases  Wed, 06/08/2011 - 22:00

(Technische Universitaet Muenchen) Amateur athletes have long suspected what sports medicine researchers at the Technische Universitaet Muenchen have now made official: evidence, gathered during the world's largest study of marathons, that consumption of non-alcoholic weissbier, or wheat beer, has a positive effect on athletes' health.

Under the direction of Dr. Johannes Scherr, physicians examined 277 test subjects three weeks before and two weeks after the 2009 Munich Marathon.


 

Residual dipolar couplings unveil structure of small molecules

EurekAlert! - Medicine and Health  Wed, 02/16/2011 - 23:00

(Technische Universitaet Muenchen) Chemists at the Technische Universitaet Muenchen and the Karlsruhe Institute of Technology introduced a new method for identifying chemical compounds.

The approach they used is an improvement on nuclear magnetic resonance measurements -- for decades one of the most successful methods for determining the chemical structure of organic molecules.

The results now published in the scientific journal Angewandte Chemie show a handy approach to structural data when classical methods of analysis fail.


 

Physicist Franz Pfeiffer receives 2011 Leibniz Prize

EurekAlert! - Cancer  Wed, 12/01/2010 - 23:00

(Technische Universitaet Muenchen) Physicist Franz Pfeiffer is one of the ten winners of the 2011 Leibniz Prize, the German Research Foundation has announced.

The 38-year-old physicist, holds the Chair for Biomedical Physics at the Technische Universitaet Muenchen.

The prize honors his fundamental and applied research in X-ray phase-contrast imaging, which promises significant progress toward early detection of tumors.

The prize is Germany's most renowned scientific award and brings each recipient 2.5 million euros in prize money.


 

Biosensor chip enables high-sensitivity protein analysis for dis...

EurekAlert! - Infectious and Emerging Diseases  Wed, 04/21/2010 - 22:00

(Technische Universitaet Muenchen) In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments.

Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show changes due to disease or medication.

The researchers have founded a startup to commercialize this generic platform for medical diagnosis, drug discovery, and proteomics.


 

Sensor biochips could aid in cancer diagnosis and treatment

EurekAlert! - Medicine and Health  Wed, 10/21/2009 - 22:00

(Technische Universitaet Muenchen) Researchers at TUM, the Technische Universitaet Muenchen, have developed a new test process -- using lab-on-a-chip technology -- for establishing whether or not a cancer patient's tumor cells will respond to a particular drug.

Such sensor biochips could potentially be used in the future to aid in rapid identification of the most effective medication for individual patients.


 

Fine-tuning an anti-cancer drug

EurekAlert! - Cancer  Mon, 08/17/2009 - 22:00

(Technische Universitaet Muenchen) Biochemists at the Technische Universitaet Muenchen, in collaboration with researchers from San Diego-based Nereus Pharmaceuticals, have illuminated a reaction pathway that blocks the action of proteasomes, vital intracellular waste-processing plants.

In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to development of custom-tailored anti-cancer drugs with improved efficacy and safety.